Paige: The AI Breakthrough Set to Redefine How Hospitals Catch Cancer
What is Paige? Paige is an AI-first digital pathology platform that accelerates and augments cancer diagnosis by applying deep-learning models to whole-slide images. The platform combines an FDA-cleared viewer, clinical-grade detection models (e.g., prostate, pan-cancer screening), and foundation-model capabilities that analyse tissue morphology and infer molecular biomarkers directly from slides. Typical workflows include pre-screening to […]
Feature Categories
What is Paige?
Paige is an AI-first digital pathology platform that accelerates and augments cancer diagnosis by applying deep-learning models to whole-slide images. The platform combines an FDA-cleared viewer, clinical-grade detection models (e.g., prostate, pan-cancer screening), and foundation-model capabilities that analyse tissue morphology and infer molecular biomarkers directly from slides.
Typical workflows include pre-screening to prioritise slides, concurrent reads to boost pathologist sensitivity and efficiency, and biomarker prediction to help stratify patients for trials or targeted therapies. Paige targets pathology labs, hospital systems, and life-science teams seeking faster, more reproducible diagnostics and earlier cancer detection across multiple tissue types. It supports high-volume clinical workloads while enabling research and translational use cases.
Why Leading Healthcare Teams Trust Paige
- Paige Prostate became the first AI-based pathology product to receive FDA de novo marketing authorisation in September 2021, improving cancer detection by 7.3% and reducing false negatives by 70% and false positives by 24%.
- The company's FullFocus viewer received FDA clearance in July 2020 and achieved IVDR CE Mark certification.
- Paige has been certified by the British Standards Institute for Quality Management in Medical Devices and has received MDSAP certification.
- Under UK regulations, Paige has received 13 UKCA marks for 18 products.
- In 2019, Paige received the first FDA Breakthrough Device designation for AI in cancer diagnosis.
- In 2025, Paige received another Breakthrough Device designation for PanCancer Detect, the first for an AI tool capable of identifying both common and rare cancer variants across different anatomic sites.
- The company partnered with Memorial Sloan Kettering Cancer Centre to access over 25 million pathology slides. This arrangement faced controversy regarding potential conflicts of interest. However, MSK clarified that only de-identified digital images and diagnostic data are shared, with no patient tissue or protected health information provided to Paige.
- Paige raised over $125 million in Series C funding from KKR, Casdin Capital, and Johnson & Johnson Innovation, bringing total funding to $195 million by 2021.
- In August 2025, Tempus AI acquired Paige for $81.25 million, including its dataset of nearly 7 million digitised pathology slides and a foundation AI model trained on over 2.3 million whole-slide images.
- Paige partnered with Microsoft to develop Virchow, a foundation model demonstrating best-in-class performance in biomarker prediction, cell identification, and pan-cancer detection.
Top 3 Pain Points Paige Fixes in Healthcare
| Problem | How Paige Solves It |
|---|---|
| 1. Slow and variable cancer detection in pathology workflows | Applies AI to analyse whole-slide images, enabling faster, more consistent identification of cancerous features. |
| 2. High diagnostic workload for pathologists | Automates pre-screening and supports concurrent reads, reducing manual burden and improving turnaround times. |
| 3. Limited early detection and biomarker insights from routine histology | Uses advanced image-based models to detect subtle disease signals and infer biomarkers directly from slides. |
Feature Category Summary: Paige
| Feature Category | Summary | Association (YES, NO, NA) |
|---|---|---|
| Regulatory-Ready | Paige has multiple FDA authorizations, including de novo marketing authorization for Paige Prostate as the first AI-based pathology product cleared for in vitro diagnostic use and 510(k) clearances for its FullFocus whole-slide image viewer, and reports three FDA Breakthrough Designations, 13 CE-IVDD marks, 13 UKCA marks, and explicit claims of GxP compliance and ISO 13485 certification for its AI technology and services, providing strong evidence of regulatory-grade processes, auditability, and validation practices. | YES |
| Clinical Trial Support | Paige’s solutions are positioned as clinical diagnostic and early detection tools integrated into routine pathology workflows and regulatory evidence (e.g., FDA submissions) is based on clinical performance studies, but public-facing materials for Paige’s diagnostic AI and platform do not describe dedicated modules for protocol design, trial feasibility, patient recruitment management, or trial reporting beyond use as a diagnostic endpoint tool. | NO |
| Supply Chain & Quality | Paige emphasizes ISO 13485 (medical device quality management) and GxP compliance for its AI technology and services, which addresses software and device quality processes, but there is no indication that Paige’s products manage pharmaceutical or device manufacturing supply chains, counterfeit detection, or batch-level production QA functions. | NA |
| Efficiency & Cost-Saving | The FDA de novo decision and press materials state that Paige Prostate helps pathologists become more accurate, reproducible, and efficient, and that FullFocus enables pathologists to manage workloads, reduce time to diagnosis, and lower turnaround times by leveraging digital workflows and AI assistance, though detailed economic studies are not prominently presented. | YES |
| Scalable / Enterprise-Grade | Paige describes its platform and FullFocus viewer as cloud-based solutions used daily by leading pathology labs worldwide, with integrations to multiple FDA-cleared scanners and claims of “open, secure and scalable API capabilities” that support large health systems and enterprise deployments, and its AI technology and services page emphasizes scalable foundation models and platform services for partners. | YES |
| HIPAA Compliant | The Paige Prostate Suite is reported in a deployment safety case to have met HIPAA compliance and ISO/IEC 27001 standards, and Paige’s AI technology and services page states that Paige is HIPAA and GDPR compliant, indicating adherence to healthcare privacy requirements for protected health information. | YES |
| Clinically Validated | FDA de novo authorization for Paige Prostate and subsequent regulatory publications reference a pivotal clinical study where use of Paige Prostate increased sensitivity of cancer detection from 89.5% to 96.8% with substantial reductions in false negatives and false positives, and a deployment safety case paper describes a structured safety and hazard analysis around real-world deployment of Paige Prostate Suite, together providing strong evidence of clinical validation for its intended prostate cancer detection use. | YES |
| EHR Integration | Paige’s integrations and platform announcements focus on interoperability with digital pathology scanners, image management systems, and third-party AI platforms (e.g., scanner vendors and pathology platforms) and highlight open APIs within digital pathology workflows, but there is no explicit, public documentation of direct integration into general EHR systems (e.g., Epic/Cerner) as a standard feature. | NA |
| Explainable AI | Published regulatory and deployment documentation describe Paige Prostate as an assistive AI that highlights regions of interest and is used by pathologists to confirm their findings, indicating some visual transparency of outputs, but there is no explicit mention of formal explainable AI techniques such as feature-attribution metrics, saliency explanations beyond ROI highlighting, or detailed model interpretability dashboards. | NA |
| Real-Time Analytics | Paige’s products operate within routine pathology workflows to assist slide review and diagnosis, and materials describe reductions in time to diagnosis and real-time viewing of AI-enhanced slide information within the viewer, but there is no explicit positioning of Paige’s platform as a real-time streaming analytics engine or continuous monitoring dashboard beyond interactive image analysis during case review. | NA |
| Bias Detection | An industry article on digital pathology platforms notes that Paige is implementing multiple procedures to combat AI bias, focusing on training practices and data curation to minimize bias in models, but does not describe a productized feature set for automatic bias detection or reporting across demographic subgroups within the deployed software. | NA |
| Ethical Safeguards | The deployment safety case for Paige Prostate Suite outlines a structured safety case, hazard and risk analysis, and continuous safety monitoring for the regulatorily approved system in use, demonstrating governance around clinical deployment and human-in-the-loop use where pathologists remain responsible for final diagnosis, but public materials do not detail configurable use-case restrictions or generalized AI governance consoles beyond this regulated workflow design. | YES |
Risks & Limitations: Paige
-
Predictive performance depends on image quality, scanning protocols, and dataset representativeness; variability in staining or scanning can reduce accuracy.
-
Outputs are decision-support and require pathologist verification before clinical action.
-
Integration with legacy LIS/PACS and lab workflows may require IT effort and professional services.
-
Regulatory and compliance review may be needed when using outputs to influence clinical decision-making or for patient selection in trials.
Tags
Share This AI Tool
Get a neutral, no obligation view of whether this AI tool fits your portfolio
Stephen
Founder of HealthyData.Science · 20+ years in life sciences compliance & software validation · MSc in Data Science & Artificial Intelligence.